13 research outputs found

    On the benefits of bringing cloud-awareness to network virtual functions

    Get PDF
    Proceeding of: 2018 European Conference on Networks and Communications (EuCNC), June 18-21, Ljubljana, SloveniaWe are currently observing the softwarization of communication networks, where network functions are translated from monolithic pieces of equipment to programs running over a shared pool of computational, storage, and communication resources. As the amount of this resources might vary over time, in this paper we discuss the potential benefits of introducing resource awareness to softwarized network functions. More specifically, we focus on the case of computational elasticity, namely, the ability to endure shortages of computational resources while providing an adequate (although non-ideal) service. We discuss how to enable this ability by re-designing network functions, and illustrate the potential benefits of this approach with a numerical evaluation

    The path towards resource elasticity for 5G network architecture

    Get PDF
    Proceeding of: IEEE Wireless Communications and Networking Conference Workshops (WCNCW 2018)Vertical markets and industries are addressing a large diversity of heterogeneous services, use cases, and applications in 5G. It is currently common understanding that for networks to be able to satisfy those needs, a flexible, adaptable, and programmable architecture based on network slicing is required. Moreover, a softwarization and cloudification of the communications networks is already happening, where network functions (NFs) are transformed from monolithic pieces of equipment to programs running over a shared pool of computational and communication resources. However, this novel architecture paradigm requires new solutions to exploit its inherent flexibility. In this paper, we introduce the concept of resource elasticity as a key means to make an efficient use of the computational resources in 5G systems. Besides establishing a definition as well as a set of requirements and key performance indicators (KPIs), we propose mechanisms for the exploitation of elasticity in three different dimensions, namely computational elasticity in the design and scaling of NFs, orchestration-driven elasticity by flexible placement of NFs, and slice-aware elasticity via cross-slice resource provisioning mechanisms. Finally, we provide a succinct analysis of the architectural components that need to be enhanced to incorporate elasticity principles.Part of this work has been performed within the 5GMoNArch project, part of the Phase II of the 5th Generation Public Private Partnership (5G-PPP) program partially funded by the European Commission within the Horizon 2020 Framework Program

    Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

    Get PDF
    Large studies in von Willebrand disease patients, including Spanish and Portuguese registries, led to identification of >250 different mutations. It is a challenge to determine the pathogenic effect of potential splice site mutations on VWF mRNA. This study aimed to elucidate the true effects of 18 mutations on VWF mRNA processing, investigate the contribution of next-generation sequencing to in vivo mRNA study in von Willebrand disease, and compare the findings with in silico prediction. RNA extracted from patient platelets and leukocytes was amplified by RT-PCR and sequenced using Sanger and next generation sequencing techniques. Eight mutations affected VWF splicing: c.1533+1G>A, c.5664+2T>C and c.546G>A (p.=) prompted exon skipping; c.3223-7_3236dup and c.7082-2A>G resulted in activation of cryptic sites; c.3379+1G>A and c.7473G>A (p.=) demonstrated both molecular pathogenic mechanisms simultaneously; and the p.Cys370Tyr missense mutation generated two aberrant transcripts. Of note, the complete effect of 3 mutations was provided by next generation sequencing alone because of low expression of the aberrant transcripts. In the remaining 10 mutations, no effect was elucidated in the experiments. However, the differential findings obtained in platelets and leukocytes provided substantial evidence that 4 of these would have an effect on VWF levels. In this first report using next generation sequencing technology to unravel the effects of VWF mutations on splicing, the technique yielded valuable information. Our data bring to light the importance of studying the effect of synonymous and missense mutations on VWF splicing to improve the current knowledge of the molecular mechanisms behind von Willebrand disease.info:eu-repo/semantics/publishedVersio

    Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study

    Get PDF
    [Objective] Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real-world setting have not often been addressed.[Methods] We report the experience of Spanish reference centers for coagulation disorders and from acquired hemophilia Spanish Registry (AHASR) from August 2012 to February 2021. Follow-up period of 30 days after aPCC withdrawal.[Results] Thirty patients with a median age of 70 years old, suffering from 51 bleeds treated with aPCC were finally evaluated. As first-line treatment, aPCC stopped bleeding in 13 of 14 (92.9%) cases. aPCC as the second line after recombinant factor VIIa failure, stopped bleeding in all cases. In 17 patients, aPCC was used far from initial bleed control as prophylaxis of rebleeding with 94% effectiveness. No thromboembolic episodes were communicated. One patient developed hypofibrinogenemia, which did not prevent aPCC from halting bleeding. No other serious adverse events possibly or probably associated with aPCC were reported.[Conclusions] This data support aPCC as hemostatic treatment in AHA with high effectiveness and excellent safety profile in acute bleeds and as extended use to prevent rebleedings, even in aging people with high cardiovascular risk.Shire IIR-ES-002899.Peer reviewe

    Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

    Get PDF
    Large studies in von Willebrand disease patients, including Spanish and Portuguese registries, led to the identification of >250 different mutations. It is a challenge to determine the pathogenic effect of potential splice site mutations on VWF mRNA. This study aimed to elucidate the true effects of 18 mutations on VWF mRNA processing, investigate the contribution of next-generation sequencing to in vivo mRNA study in von Willebrand disease, and compare the findings with in silico prediction. RNA extracted from patient platelets and leukocytes was amplified by RT-PCR and sequenced using Sanger and next generation sequencing techniques. Eight mutations affected VWF splicing: c.1533+1G>A, c.5664+2T>C and c.546G>A (p.=) prompted exon skipping; c.3223-7_3236dup and c.7082-2A>G resulted in activation of cryptic sites; c.3379+1G>A and c.7437G>A) demonstrated both molecular pathogenic mechanisms simultaneously; and the p.Cys370Tyr missense mutation generated two aberrant transcripts. Of note, the complete effect of three mutations was provided by next generation sequencing alone because of low expression of the aberrant transcripts. In the remaining 10 mutations, no effect was elucidated in the experiments. However, the differential findings obtained in platelets and leukocytes provided substantial evidence that four of these would have an effect on VWF levels. In this first report using next generation sequencing technology to unravel the effects of VWF mutations on splicing, the technique yielded valuable information. Our data bring to light the importance of studying the effect of synonymous and missense mutations on VWF splicing to improve the current knowledge of the molecular mechanisms behind von Willebrand disease. clinicaltrials.gov identifier:02869074

    Pregnancy-associated acquired haemophilia A: Results from the European Acquired Haemophilia (EACH2) registry

    No full text

    Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)

    No full text
    corecore